Estudo randomizado | Telaglenastate falhou em melhorar a eficácia do cabozantinibe em pacientes com carcinoma de célula renal avançado.

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial – JAMA Oncology (gratuito por tempo limitado)

Comentário no Twitter

The CANTATA randomized trial of the glutaminase inhibitor telagenastat or placebo added to cabozantinib in patients with metastatic clear cell renal cell carcinoma (RCC) demonstrated no improvement in efficacy with addition of telagenastat https://t.co/r9j2wmjnlF #GUCSM pic.twitter.com/ovXXEAXqi0

— JAMA Oncology (@JAMAOnc) September 1, 2022